InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,421.94
(
-1.48%
)
US TECH 100
17,970.00
(
-2.56%
)
Dow Jones
40,424.71
(
-0.81%
)
Brent Oil
71.04
(
-2.38%
)
Bitcoin
54,290.16
(
-3.34%
)
Post# of 253052
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 838
Posts 120382
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: RNsidersbuying post# 239199

Wednesday, 06/08/2022 8:59:32 AM

Wednesday, June 08, 2022 8:59:32 AM

Post# of 253052
RIGL—(-46%/PM)—misses phase-3 primary endpoint:

https://finance.yahoo.com/news/rigel-announces-top-line-results-110000141.html

Rigel Pharmaceuticals…today announced top-line efficacy and safety data from the FORWARD Phase 3 clinical trial, a global, multi-center, randomized, double-blind, placebo-controlled trial of fostamatinib in patients with warm autoimmune hemolytic anemia (wAIHA). The trial did not demonstrate statistical significance in the primary efficacy endpoint of durable hemoglobin response in the overall study population.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up